Audit in process? Call the number on your audit letter to get options.
Site Logo
Health care professionals website
DPL Global Search
DPL Utility Nav
DPL Main Nav
DPL Global Search
DPL Utility Nav
Breadcrumbs
SubHero Banner
RxNews®
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Zulresso® (brexanolone) – Expanded indication
June 16, 2022 - The FDA approved Sage Therapeutics’ Zulresso (brexanolone), for the treatment of postpartum depression (PPD) in patients 15 years and older.
